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Rabies is a viral zoonosis transmitted by vampire bats across Latin America. Substantial
public health and agricultural burdens remain, despite decades of bats culls and livestock
vaccinations. Virally vectored vaccines that spread autonomously through bat populations are
a theoretically appealing solution to managing rabies in its reservoir host. We investigate the
biological and epidemiological suitability of a vampire bat betaherpesvirus (DrBHV) to act as
a vaccine vector. In 25 sites across Peru with serological and/or molecular evidence of rabies
circulation, DrBHV infects 80–100% of bats, suggesting potential for high population-level
vaccine coverage. Phylogenetic analysis reveals host specificity within neotropical bats,
limiting risks to non-target species. Finally, deep sequencing illustrates DrBHV super-
infections in individual bats, implying that DrBHV-vectored vaccines might invade despite the
highly prevalent wild-type virus. These results indicate DrBHV as a promising candidate
vector for a transmissible rabies vaccine, and provide a framework to discover and evaluate
candidate viral vectors for vaccines against bat-borne zoonoses.
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Common vampire bat (Desmodus rotundus)-transmittedrabies virus (VBRV, species Rabies lyssavirus, genus Lys-savirus, family Rhabdoviridae) is almost invariably fatal in
mammals, including humans1. Across Latin America, VBRV
mortality in livestock is estimated to cause losses of over US$30
million per year2, and in many countries the number of vampire
bat-to-human rabies cases now surpasses those attributed to dogs
or wild carnivores3. Strategies to limit the burden of VBRV have
had limited success4. Human vaccination coverage is poor in the
geographically isolated communities where outbreaks are most
pervasive, and, although pre-exposure vaccination of livestock is
effective, it is not sufficiently widely adopted to prevent major
losses owing to the relatively high costs to subsistence farmers5.
In most Latin American countries, vampire bat populations are
also controlled using anticoagulant poisons6. Culls reduce
populations of vampire bats but mathematical models and field
experiments suggest that appreciable reduction of the burden of
VBRV might require coordinating intensive culls across
impractically large geographical areas7–10.
Vaccination of wildlife reservoirs is a tried and tested method
of rabies control in terrestrial reservoir hosts. Large-scale rabies
vaccination programmes using oral vaccines distributed in baits
successfully controlled or eradicated rabies in much of Europe
and North America11,12. Despite the resounding success of these
vaccination campaigns, similar attempts to target bats, the pri-
mary source of human rabies exposure in much of the Americas,
face unresolved challenges. Primary amongst these is finding a
method of scalable vaccine delivery that achieves sufficiently high
population-level coverage in remote and often inaccessible wild
bat populations to alter viral transmission dynamics.
Vaccines that spread unaided between individuals (‘transmis-
sible vaccines’) have been proposed as a potential solution, since
high population level coverage might be attained from a limited
number of initial deployment efforts13. Such vaccines are
increasingly feasible to generate in the laboratory by engineering
naturally present, replication competent viruses as vectors to
express immunogenic proteins from the pathogenic virus of
interest (hereafter, ‘target virus’)14. Given high degrees of social
interaction that would promote vaccine spread and long lifespans
and low reproductive rates that would preserve population-level
immunity, transmissible vaccines could be particularly effective in
many bat species, including vampire bats.
To date, real-world applications of transmissible vaccines have
been hampered by safety and efficacy constraints rooted in virus
biology, with only one reaching field trials13. In contrast to non-
transmissible vaccines where virulence can be genetically atte-
nuated, transmissible vaccine vectors may need to be inherently
non-pathogenic, since sustained spread would pose unacceptably
high risks of reversion to virulence (e.g., as observed during
unintended spread of live-attenuated polio vaccines15). To ensure
safety in non-target species, transmissible vaccines should be host
specific16, and to be effective, they must reach high population-
level prevalence of infection. More specifically, a key theoretical
criterion for eradication of the target virus is that the basic
reproductive number of the vaccine must exceed that of the target
virus17. High vaccine transmissibility may be difficult to achieve
for at least two reasons. First, the genomic engineering that
converts wild-type viruses into vaccines is likely to reduce
transmission14. Second, immunological cross-reactivity of viral
vectors with already circulating wild-type viruses may impede
vaccine invasion18. Ideal vectors should therefore be benign,
commonly occurring, host-specific viruses that can infect indi-
viduals that have already been infected by the wild-type version of
the viral vector (i.e., capacity for ‘super-infection’)14,15,19.
One group of viruses that offers promising transmissible vac-
cine vector candidates is the subfamily Betaherpesvirinae in the
family Herpesviridae (known as betaherpesviruses, BHVs). These
large, double-stranded DNA viruses are typically ubiquitous in
their hosts, causing lifelong latent infections with occasional
reactivation, e.g. human cytomegalovirus (HCMV)20. BHVs are
largely host-specific, and healthy adults usually show no overt
signs of disease. BHVs can also reach high population-level
prevalence are transmitted via multiple routes in bodily fluids
(faecal matter, saliva, etc.), and possess a remarkable capability for
super-infection18,20–22. Finally, BHV vectors induce potent
immunological responses that are often equally or more powerful
and longer lasting than those induced by natural infections with
target viruses23. The immune response is also potentially self-
boosting given the propensity for latency and reactivation of
herpesviruses. As a result, BHV vectors have been successfully
developed to target a variety of pathogens. These include murine
cytomegalovirus-vectored vaccines for Mycobacterium tubercu-
losis24 and rhesus macaque cytomegalovirus-vectored vaccines for
Plasmodium malaria25, Ebola, and HIV/SIV26–28. However, none
of these examples currently utilise the transmissible potential
of BHVs.
Bats maintain BHVs globally29–31, opening the tantalising
possibility that these viruses might be exploited to vaccinate bat
reservoirs against zoonotic viruses, pre-empting their emergence
in humans or domestic animals. In the context of VBRV, virally
vectored vaccines have been widely discussed as an alternative to
culling. However, existing vectors, including vaccinia virus and
raccoonpox virus, infect diverse mammalian species, including
humans32–35 and therefore have deliberately attenuated capacity
for shedding and transmission. Hypothetical BHV vectors may
offer a solution: a host-specific, transmissible rabies vaccine.
Although BHVs in D. rotundus have not been formally described,
a recent metagenomic study reported sequences related to BHVs
in several pools of saliva samples from Peru29.
Here, we report field and genomic studies describing this virus
(hereafter DrBHV) and assess its suitability for further study as a
vector for a transmissible rabies vaccine. Specifically, we address
three central objectives: (1) to quantify BHV prevalence across
populations and demographic groups of vampire bats in Peru, (2)
to examine VBRV seroprevalence, prevalence and distribution to
determine the potential use of a BHV vector for targeting rabies,
(3) to use phylogenetic analyses of DrBHV and other BHVs to
investigate the host specificity of DrBHV, and (4) to use deep
sequencing to evaluate the potential for DrBHV super-infections
in individual bats and obtain a whole genome sequence to eval-
uate the structural similarity of DrBHV to already developed
BHV vectors.
Results
High prevalence of BHV infection in D. rotundus. We used a
semi-nested PCR of the highly conserved BHV UL89 to assess
rates of BHV infection in 21 bat species (N= 111 individuals)
that co-roost with D. rotundus, as well as 128 D. rotundus indi-
viduals from 22 sites across Peru. This sampling revealed BHV
infection in nine bat species, spanning all three families of New
World bats sampled: Phyllostomidae, Vespertilionidae, and
Emballonuridae (Fig. 1).
Relative to the other New World bats that we sampled and
results from previous studies in other bat species, BHVs were
detected at particularly high frequency in D. rotundus, even after
controlling for sample size differences among species (Fig. 1,
Supplementary Table 1 and 2). In total, 96.9% (124/128) of the
vampire bat saliva samples were BHV-positive by semi-nested
PCR, with 46.9% (60/128) positive after a single round of PCR.
All age classes, adults (N= 74), juveniles (N= 39) and sub-adults
(N= 15), were infected. A Generalised Linear Mixed Model
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(GLMM) showed that none of the fixed or random effects tested
(site, age, sex, eco-region, year, season and colony structure—
vampire bats only, or co-roosting with other bat species)
significantly affected BHV detection (Supplementary Table 3).
Three bats were sampled at multiple time points from 2015–2018,
and 3/3 were positive at all time points. BHVs were also detected
in 40% (17/41) of D. rotundus blood samples. All 11 bats for
which paired samples (both saliva and blood) were tested were
positive in saliva, and 45% (5/11) were also positive in blood,
confirming systemic infection of bats rather than potential (but
unlikely) contamination of saliva from feeding. A lower
prevalence in blood compared to saliva has also been observed
in HCMV, as viremia is sporadic in actively infected
individuals36.
Widespread distribution of VBRV in D. rotundus. Eradicating
zoonoses using transmissible vaccines requires that vaccines
transmit better than the targeted zoonosis17. We therefore eval-
uated the prevalence of active VBRV infection (viral shedding)
and past exposure (virus neutralising antibodies) in wild vampire
bats across Peru. Of the 128 individuals from which saliva sam-
ples were tested for DrBHV, 123 could also be tested for the
presence of VBRV RNA using a nested reverse transcription (RT)
PCR targeting the nucleoprotein gene. The prevalence of active
rabies infection among vampire bats was low (0.8%), with only
one individual RT-PCR positive (Bat ID: 6024, Site: CAJ4, Year:
2016). Sequencing this amplicon and BLASTn showed that this
virus was most genetically similar to viruses we previously
sequenced from livestock in this department of Peru37. Among 99
of the individuals previously tested by BHV PCR, with serum
samples available, 12 (12.1%) had rabies virus neutralising anti-
bodies >= 0.166 International Units (Supplementary Data 1).
Analysis of a larger set of vampire bat sera from 2015 to 201738
revealed spatial and temporal variation in seroprevalence (ran-
ging from 0 to 35%) in areas of Peru where rabies outbreaks occur
in livestock, presumably reflecting the spatial metapopulation
dynamics that underpin VBRV endemicity7,39 (Fig. 2).
Phylogenetic separation and host specificity of bat BHVs.
Bayesian phylogenetic analysis of the UL89 nucleotide (304 bp)
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Fig. 1 Widespread BHV infection across the bat phylogeny. The bat phylogeny (left) was extracted from the mammalian super-tree to contain species
that were tested here or elsewhere for BHV infection30,71. Labels on tree branches indicate bat families. Taxa in black text indicate bat species tested here
for the first time. Stacked bar charts (right) indicate the number of saliva samples that tested either positive or negative for BHV by PCR of the terminase
gene UL89. A binomial generalised linear mixed model (GLMM) followed by post-hoc pairwise comparisons of estimated prevalence by species (multiple
comparisons of means: Tukey contrasts, two tailed) was used to test the significance of differences in prevalence. The pairwise significance of prevalence
in each species compared to D. rotundus is shown on the bar chart with corrected P-values: > 0.1, * > 0.05, ** > 0.01, *** > 0.005. All other pairwise
comparisons were non-significant. D. rotundus is indicated with a red arrow. Source data are provided as a Source Data file.
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and amino acid sequences obtained from Peruvian bats, as well as
sequences from other bat and non-bat BHVs on GenBank, was
carried out to evaluate whether sympatric bat species shared
common BHVs or maintained phylogenetically compartmenta-
lised, host-associated viruses and to evaluate broader evolutionary
patterns of co-speciation and host shifting among mammals. The
nucleotide tree (Fig. 3, main image) revealed distinct, host-species
associated clades in the bat species with multiple samples (D.
rotundus, Glossophaga soricina, Myotis oxyotus). Those with only
one sample per species (e.g. Sturnira tildae, Saccopteryx bilineata,
Rhynchonycteris naso) also had distinct viruses that may also
comprise host-associated clades. The strongly supported D.
rotundus – associated clade (hereafter, DrBHV) contained
sequences from vampire bat populations across Peru and no
vampire bat-derived samples occurred elsewhere in the phylo-
genetic tree. At even broader geographic levels, BHVs from bats
in the genus Myotis clustered together, despite being sampled on
different continents, with a single clade comprising of viruses
from Peru and Spain, suggesting ancient circulation of BHVs in
this genus. The exception to viral compartmentalisation by bat
taxonomy was a sample taken from a single Artibeus lituratus bat
(total sample size n= 2, positive=1) which clustered within
DrBHV. Cytochrome B PCR and sequencing confirmed that this
sample originated from an A. lituratus bat, suggesting a possible
cross-species infection within the family Phyllostomidae. At
deeper nodes, both bat BHVs as a whole and viruses from indi-
vidual bat families (i.e. Phyllostomidae and Vespertilionidae)
formed paraphyletic groups; however, these branches were poorly
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Fig. 2 Seroprevalence of VBRV in D. rotundus and geographic distribution of outbreaks in cattle. a–f The seroprevalence of VBRV in D. rotundus,
grouped by year and department within Peru, are shown in the surrounding plots (a–f), with the location of each department marked by the corresponding
letter on the map. Seroprevalence within a department is displayed as the mean average with 95% confidence intervals based upon sample size. Sample
sizes for A-F in ascending year order are as follows: A-5, 21; B-144, 126; C-158, 72, 116; D-107, 181, 218; E-146, 167, 78; F-45, 24, 111. g Locations of
laboratory confirmed rabies mortality in livestock between 2015 and 2017 are shown coloured by year (2015=red, 2016=yellow, 2017=blue) on the map
of Peru. The location from which the PCR positive bat saliva sample originated is shown by the black diamond. Source data are provided as a Source
Data file.
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supported (posterior probabilities <0.85) relative to the
>0.95 support for the host-species specific clades (Fig. 3). The
phylogenetic analysis of the amino acid sequences reduced the
distinction between closely related viruses, but largely recovered
the monophyly of bat-associated BHVs and revealed bat-family
associated viral clades (Fig. 3, inset). One exception was a BHV
recovered from the hairy-legged vampire bat (Diphylla ecaudata)
which grouped more closely with the tupaiid (common tree
shrew, Malaysia) BHV than bat BHVs.
We next carried out a host-virus co-phylogenetic analysis to
quantify support for co-speciation versus host shifting in the
evolution of bat herpesviruses, and therefore the potential for
future host shifts. The co-phylogenetic analysis, in which the
virus phylogeny is scaled to fit the host phylogeny, calculates the
global sum of squared residuals (m2xy) for the observed host-virus
network, and compares this to those of randomly generated
interaction networks, producing a null distribution of m2xy values.
The analyses indicated significant congruence between the host
species phylogeny and the maximum clade credibility trees of
BHVs at both the (a) nucleotide (m2xy= 3.535, P < 0.001, null
m2xy= 6.671, standard deviation [SD]= 0.358) and the (b) amino
acid levels (m2xy= 1.572, P < 0.001, null m2xy= 6.315, SD=
0.355), where none of the 10,000 random networks showed more
phylogenetic congruence than the observed network. Since
variable posterior support at deeper nodes in BHV phylogenies
indicated considerable uncertainty which could influence the co-
evolutionary analyses, we repeated this analysis on 100 trees that
were randomly sampled from the posterior distributions of each
phylogenetic analysis, both of which showed congruence between
host and virus trees (average values of test statistics over 100 trees:
9235_CUS8/Desmodus_rotundus/DrBHV
8211_AYA11/Desmodus_rotundus/DrBHV
8209_AYA11/Desmodus_rotundus/DrBHV
9283_API1/Desmodus_rotundus/DrBHV
8383_CAJ4/Desmodus_rotundus/DrBHV
9256_API140/Desmodus_rotundus/DrBHV
8381_CAJ4/Desmodus_rotundus/DrBHV
9258_API140/Desmodus_rotundus/DrBHV
8038_HUA4/Desmodus_rotundus/DrBHV
9232_CUS8/Desmodus_rotundus/DrBHV
9282_API1/Desmodus_rotundus/DrBHV
8036_HUA4/Desmodus_rotundus/DrBHV
8408_AMA2/Desmodus_rotundus/DrBHV
Arti_li_2_LR4/Artibeus_lituratus/BHV
8409_AMA2/Desmodus_rotundus/DrBHV
Glossophaga_s_LR4/Glossophaga_soricina/BHV
AY8_LR1/Glossophaga_soricina/BHV
Glossophaga_2_LR4/Glossophaga_soricina/BHV
B3_LR2/Glossophaga_soricina/BHV
HG531783.1/Caviid/BHV_2
AF281817.1/Tupaiid/BHV_2
6252_1_AMA2/Diphylla_ec audata/BHV
KX839485.1/Gorilla_beringei_beringei/CMV_2
KP745648.1/Homo_sapien/HHV_5
KX839487.1/Gorilla_beringei_beringei/CMV_1
AF480884.1/Panine/BHV_2
FJ483970.2/Aotine/BHV_1
KX689268.1/Macacine/BHV_3
AY536265.1/Cercopithecine/HV_8
JN227533.1/Cynomolgus_macaque/CMV
U68299.1/Mouse/CMV_1
AF232689.2/Rat/CMV
Saccopteryx_1_LR4/Saccopteryx_bilineata/BHV
R_naso_1_LR4/Rhynchonycteris_naso/BHV
Sturnira_1_LR4/Sturnira/BHV
JX294564.1/Tadarida_teniotis/BHV_2
MO_3_CAJ3/Myotis_oxyotus/BHV
MO_1_CAJ1/Myotis_oxyotus/BHV
KT886845.1/Myotis_escalerai/BHV_2
CH3_LR3/Myotis_oxyotus/BHV
JX294566.1/Rousettus_aegyptiacus/BHV_2
JX294560.1/Pipistrellus_pygmaeus/BHV_1
JX294558.1/Pipistrellus_pipistrellus/BHV_1
JX294559.1/Pipistrellus_pipistrellus/BHV_2
JX294556.1/Nyctalus_noctula/BHV_1
JX294562.1/Plecotus_austriacus/BHV_2
EF151197.1/Miniopterus_schreibersii/BHV_1
KY290185/Homo_sapien/HHV6
0.0 0.1 0.2 0.3
Substitutions/site
Host species order/family
(Ch)−Emballonuridae (Ch)−Miniopteridae (Ch)−Molossidae
(Ch)−Phyllostomidae (Ch)−Pteropodidae (Ch)−Vespertilionidae
(R)−Caviidae (R)−Muroidea (R)−Scandentia
Primate
0.00 0.05 0.10 0.15 0.20 0.25
Substitutions/site
Ves
Emb
Phy
PhyDiphylla ecaudata
Pri
Pri
Mur
Min
Pte
Mol
Cav
Sca
Posterior support: >= 0.95 < 0.95 &>= 0.85 < 0.85 &>= 0.50 <0.50
Fig. 3 Bayesian phylogenetic tree of mammalian BHV shows clustering of virus diversity by host taxonomy. Nucleotide-based phylogeny of
UL89 sequences (304 bp) showing clusters of BHVs that were generally restricted to single species. Posterior probabilities are represented by node colour.
Tip labels are coloured according to host taxonomy (family level for orders Chiroptera and Rodentia, and order level for Primates) and include the host
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(a) m2xy= 3.616 SD= 0.360, P < 0.001; (b) m2xy= 1.519 SD
= 0.335, P < 0.001). A jackknife procedure testing how each
host-virus link contributed to the overall measure of congruence
found that 61 and 56% of the host-virus links were congruent in
the amino acid tree and nucleotide tree, respectively (95%
confidence interval below the mean of all squared jackknife
residuals; Fig. 4). Support for the primate and rodent links was
much higher in the amino acid tree compared to the nucleotide
tree (all link supports can be found in Supplementary Table 4),
reflecting the separation of bat viruses into a monophyletic clade.
The position of the BHV from Diphylla ecaudata was
incongruent with the host phylogeny in both analyses, excluding
co-divergence of this virus.
DrBHV capacity for super-infection and genomic organisa-
tion. To determine the presence of multiple strain infections
within individuals, two PCR-positive D. rotundus saliva samples
(IDs 10144 and 10148, see Supplementary Table 5 for details)
were selected for shotgun metagenomic sequencing. Reads from
10148 were used to generate a consensus 231kbp consensus
genome. Re-mapping reads to the consensus genome revealed
4779 nucleotides (~2%) that had single nucleotide polymorph-
isms (SNPs) in which more than 10% of reads differed from the
consensus. The distribution of SNPs varied across the genome
(0.7–5.4% of positions, analysed in 1000 bp sections). Compar-
isons of short sections of the genome spanned by multiple unique
reads revealed linked SNPs, and enumeration of such reads in
areas of high coverage corroborated the presence of multiple
unique DrBHV strains in both bats (Fig. 5). Due to the size of
reads produced by shotgun sequencing (150 bp), and the low
coverage depth (average 8.28 reads/base), it was only possible to
use short windows (50 bp) for analysis; it was therefore difficult to
quantify how many strains were present in each bat. Despite this,
sample 10148_KF29 contained two major strains in each window
tested, which differed by >10% at the nucleotide level (Fig. 5).
Lower coverage in sample 10144_KF29 meant that distinguishing
true strains from sequencing error was not always possible.
However, two sequences which met our criteria for being con-
sidered distinct strains were observed in some locations (Fig. 5a,
C), one of which was identical to a strain found in sample
10148_KF29 (Fig. 5c), supporting a multiple-strain infection.
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Fig. 4 Co-phylogenetic analysis of hosts and betaherpesviruses reveal co-evolution across mammals. Co-phylogeny of host species (phylogeny
extracted from the mammalian super tree71) (left) with BHV, based on viral nucleotide (a) and amino acid (b) sequences. The lines between trees show
links between virus and host phylogenies and are coloured by host family. Link weight is inversely proportional to the PACo squared residual for each
species; heavier lines therefore reflect the likelihood that a pair represents a co-evolutionary link.
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Due to the presence of multiple strains within both samples,
the consensus DrBHV genome sequence (reconstructed from the
higher-coverage sample 10148; Supplementary Table 5) was
chimeric. Nevertheless, this sequence showed a similar gene
organisation and length to other BHVs (Supplementary Fig. 1).
Genome annotation showed highest protein similarity by
BLASTx to the bat Miniopterus schreibersii BHV B7D8
(223kbp) genome, the only available complete bat-derived BHV
genome, although 24/114 predicted proteins had insufficient
BLAST similarity to be assigned (ORFs predicted by GeneMarkS).
Recombinant BHV vaccines have inserted genes into several
locations along the vector genome, including UL8240 (encoding
for IE protein pp71) in HCMV, IE241 in MCMV, and RhCMV
ORF Rh21125,42,43 (US27), Rh10743, Rh11042, and Rh186-925
(US8-11). Whilst similar coding regions within DrBHV could not
be identified for all of the above proteins, a homologue for UL82
in DrBHV could serve as a potential site for VBRV glycoprotein
insertion.
Discussion
Preventing zoonoses by controlling transmission within natural
animal reservoirs offers an exciting complement to ongoing
efforts to manage these infections after they enter human and
domestic animal populations. This study shows how integrating
information from metagenomic sequencing, field studies and viral
genomics can begin to overcome the logistic hurdles to managing
zoonoses within inaccessible wildlife populations. Utilising long
running field studies in vampire bats, we have identified char-
acteristics of a betaherpesvirus, DrBHV, that make it a promising
candidate for further study as a transmissible vector for vaccine
targeting vampire bat rabies.
Our co-phylogenetic analyses confirm and extend BHV co-
evolution with mammals44. However, despite the pattern of
strong host-association, we found two possible exceptions. First,
we observed one A. lituratus fruit bat infected with the vampire
bat-associated BHV. The lack of divergence of this virus from
DrBHV most parsimoniously is explained by a cross-species
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Fig. 5 Metagenomic sequence data reveal multi-strain DrBHV infections in individual bats. The phylogenies (left), nucleotide sequences (centre), and
read count (right) of DrBHV strains present in the alignment of samples 10148_KF29 and 10144_KF29 (where read depth was sufficient for reads to be
included) with the DrBHV consensus genome sequence. Nucleotide locations: (a) 47620– 47671 (equivalent to part of Miniopterus schreibersii BHV B7D8
B36), (b) 121057–121108 (B70), (c) 141567–141618 (B85) and (d) 229640–229691 (B161). These locations were selected due to high coverage depth in
sample 10148_KF29. The tree tips are coloured by the individual bat from which the sequence originates.
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transmission event that had little or no onward transmission in A.
lituratus at the time of our sampling or by a contaminating
presence of DrBHV in the oral cavity of A. lituratus without
actual infection (Fig. 1). Interestingly, rabies transmission has also
been noted between these species and is potentially explained by
their frequent ecological overlap together with their evolutionary
relatedness within the family Phyllostomidae45,46. Given our low
sample size for A. lituratus, further instances of cross-species
transmission may be found, and this also holds true for other
species of bats within Phyllostomidae that roost with D. rotundus
and were poorly sampled, such as G. soricina. Additional sam-
pling is required to determine the true frequency of BHV trans-
mission among phyllostomid bat species. Second, we observed a
BHV in Di. ecaudata that was paraphyletic to all other bat BHVs.
Given that this species feeds on the blood of birds and wild
mammals, we suspect the unexpected evolutionary placement of
this virus may be a result of dietary contamination acquired from
infected prey. Additional testing of Di. ecaudata, particularly
using blood samples, would be helpful to exclude active infection
with this virus and to evaluate whether Di. ecaudata maintains
other BHVs that group within the larger bat clade, but were
missed due to our limited sampling of this species (N= 2). Aside
from these exceptions, BHVs formed taxon-associated clusters
within bats, consistent with host specificity. Given the expected
host specificity of BHVs20,47 and the epidemiological and co-
evolutionary results shown here, the available evidence most
strongly argues that DrBHV-vectored vaccines would be unlikely
to infect mammals outside of the Phyllostomidae family of New
World bats and may only rarely spread beyond D. rotundus.
We observed a high prevalence of BHV infection in vampire
bats relative to other bat species. This pattern may be explained
by the high levels of social grooming within this species as well as
food sharing through regurgitation of blood, both of which could
facilitate BHV transmission in saliva48. Since the prevalence of a
wild-type virus reflects the hypothetical maximum coverage that
it would achieve as a vector, the prevalence of DrBHV in vampire
bats implies that a rabies vaccine vector based on this virus might
infect and vaccinate nearly all individuals. Nevertheless, we
emphasise that this estimate represents an upper bound since the
addition of a target virus gene into DrBHV may diminish
transmissibility. Moreover, our metagenomic sequencing revealed
that multiple BHV strains likely co-circulate in vampire bat
populations. Strain-specific prevalence may therefore be the most
appropriate proxy for the maximum achievable vaccine coverage.
Although our PCR was not suited to defining evolutionarily
independent strains within vampire bats, future studies using
strain-specific diagnostics are needed to estimate the frequency,
intensity and geographic scope of vaccination that would be
necessary to control or eliminate VBRV.
Importantly, lower efficiency spread than implied by our global
prevalence estimates may actually be desirable. From a safety
standpoint, transmissible vaccines should have the minimum
transmissibility to meet management needs and even weakly
transmissible vaccines are predicted to be surprisingly effective in
disease control10,17. Indeed, the more ambitious aim of eradica-
tion only requires greater transmissibility of the vaccine than the
target zoonosis (R0,Vaccine > R0,Target). For VBRV, persistence
relies on metapopulation structure and R0 within single vampire
bat colonies is estimated to be < 17. Consistent with other field
studies, our serological and RT-PCR findings that a sizable
minority of bats are exposed to rabies virus, but few succumb to
productive infections, further supports the low transmissibility of
VBRV8. Moreover, bats with antibodies acquired from natural
VBRV exposures are likely to have a degree of protective
immunity7,49, further lowering the transmissibility requirements
for a DrBHV-vectored rabies vaccine. Although the R0 of DrBHV
cannot be calculated from our data, infection of nearly all vam-
pire bats suggests its transmissibility likely exceeds that of VBRV.
Our results therefore imply that a significant reduction of VBRV
might in principle be achievable with a DrBHV vectored rabies
vaccine with similar properties to the wild-type viruses that we
studied.
Persistent, life-long infections of vampire bats by DrBHV were
expected given the well-established ability of other BHVs to
undergo phases of latency, in which viral load is low and no
shedding occurs, and reactivation, in which viral load increases
and shedding resumes25. Indeed, several lines of evidence shown
here support persistent infections. First, acute infections would
not be expected to have the consistently high prevalence across
space and time that we observed for DrBHV. Second, although we
were unable to conclusively rule out sequential re-infections, we
found that 3/3 bats sampled multiple times between 2015 and
2018 remained infected up to four years after initially being BHV-
positive. Third, we observed bats with low levels of DrBHV in
saliva (as indicated by lack of detectable virus DNA in round 1 of
the PCR), which we hypothesise may have been sampled during
the latent phase of infection50. If latency and reactivation are
preserved in the vaccine vector, reactivations might naturally
boost immune responses to VBRV over the course of the vacci-
nated bat’s lifetime, while potentially providing additional
opportunities for vaccine transmission.
Capacity for multiple-strain infections is a key prerequisite for
virally vectored transmissible vaccines, since immune responses
to wild-type versions of the vector might inhibit vaccine spread18.
In both individuals tested, our metagenomic data showed mul-
tiple sequences corresponding to at least two distinct strains,
indicative of naturally occurring super-infections. Co-
transmission of multiple variants is unlikely to be the sole
explanation given the well-documented capacity of BHVs to
super-infect. For example, in cytomegaloviruses and mur-
omegaloviruses, down-regulation of MHC-class 1 on infected
cells prevents communication of infection to T-cells, allowing
frequent super-infections despite the large and lifelong T-cell and
antibody response elicited by primary infections22,51,52. Within-
host evolution occurs in persistent HCMV infections53 and may
also explain some of the DrBHV polymorphisms we observed
separating very closely related strains. However, given the slow
evolutionary rate of BHVs, which is comparable to that of other
DNA viruses, strain divergences of up to 15% in single bats can
only be explained by super-infection or transmissions of multiple,
evolutionarily distinct strains. The presence of both closely related
and distantly related strains in a single bat suggests both intra-
host evolution and super-infection (Supplementary Fig. 2).
Beyond superinfection of divergent strains, an ideal vector would
also re-infect individuals previously infected with the same strain
of virus. This is because the inevitable loss of recombinant
material from the vaccine may create viable mutants that compete
with the intact vaccine strain. The existence of multiple variants
of DrBHV (Fig. 5), raises the possibility that several strains cir-
culate around Peru, each with its own prevalence and geographic
range. Population genetics of both vampire bats and VBRV
support this prediction, showing major barriers to gene flow
among geographical regions of Peru37,54. Therefore, DrBHV
strains that are locally prevalent in one area could be engineered
and released in other areas where they do not self-compete, cir-
cumventing competition with wild-type viruses of the same strain
as the vaccine. Understanding whether mutant vaccine derived
strains may frustrate longer term vaccine applications requires
same-strain reinfection experiments in captive bats. Longitudinal
monitoring of vaccine-infected individuals is also needed to
quantify the dynamics of latency, reactivation and super-
infection55,56.
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Numerous obstacles must be resolved prior to deploying
DrBHV as a transmissible rabies vaccine. Although our data are
consistent with transmission in saliva, detection of viral DNA in
blood suggests systemic infection and the possibility of trans-
mission through additional bodily fluids, or transplacental
transmission, as can occur for HCMV57. The geographic struc-
ture of DrBHV populations would also determine the spatial
distribution of vaccines, in regards to both initial deployment,
and predicted range and timescale of spread. Phylogenetic studies
of different strains over time could be one way to better under-
stand spatiotemporal spread. Safety and regulatory issues must
also be carefully considered. For example, WHO guidelines for
recombinant dog rabies vaccines discourage those with potential
to be shed and spread infectiously (http://www.who.int/rabies/
resources/Oral_Vaccination_of_Dogs_Against_Rabies/en/).
Although these guidelines were based on the presumption that
vaccines would be attenuated forms of pathogenic viruses, addi-
tional safety testing, perhaps in conjunction with a modernisation
of the regulatory environment, will be required prior to field trials
of DrBHV-vectored rabies vaccines. Advances in deliberately
transmissible therapies in other areas of disease control, ranging
from early stages of concept development (e.g. use of genetically
heritable CRISPR-edited genes to generate Lyme disease-resistant
mice58), to limited experimental trails (e.g., immunocontracep-
tion59), to large-scale applications (e.g., release of Wolbachia-
infected mosquitoes to combat dengue virus infections), and
provide frameworks to guide how new technologies can be
applied rationally. Finally, we emphasise that our work involved
partial sequencing of wild-type viruses, which were used as a
proxy for a still-hypothetical vaccine. A vital next step would be
to isolate DrBHV strains so that their biological properties (such
as capacity for latency, re-activation and super-infection) can be
confirmed in vitro and in vivo and so that a vaccine can be
engineered and confirmed to retain these desirable properties.
In summary, we have identified a BHV in common vampire
bats (DrBHV) that meets the ecological, epidemiological and
virological prerequisites of an ideal transmissible vaccine vector.
Given that VBRV is naturally prone to extinction and that our
results suggest efficient DrBHV transmission across all demo-
graphic groups and populations of vampire bats tested, a pro-
tective DrBHV-vectored vaccine that transmits similarly to or
even less efficiently than wild-type DrBHV could conceivably
eliminate VBRV circulation. Importantly, VBRV and most other
bat-associated rabies viruses are maintained in species-specific
transmission cycles without alternative hosts that could otherwise
compromise vaccination campaigns37,60. Moreover, rabies vac-
cines are broadly protective across Rabies lyssavirus strains and
even protect against other lyssaviruses, suggesting that viral
antigenic evolution would not be a relevant barrier61,62. Finally,
decades of experience in vampire bat population control have
equipped most Latin American countries with the operational
capacity to implement vaccination campaigns alongside or in lieu
of culling efforts. Although BHVs may not be suitable vectors for
all bat-associated viruses, we illustrate that combining viral
metagenomics, field studies and co-evolutionary approaches can
identify promising candidate vectors. This approach could be
applied to any bat species for which reservoir-targeted disease
control is desirable to prevent zoonotic spillover. We encourage
serious consideration of the potential for recombinant virally
vectored vaccines to control zoonotic bat viruses within their
reservoir hosts.
Methods
Sample collection. Bats were captured between 2015 and 2018 at 37 sites across
eight administrative regions (Amazonas, Apurímac, Ayacucho, Cajamarca, Cusco,
Huánuco, Lima and Loreto) of Peru. Bats were captured using mist nets and harp
traps, then placed in individual cloth bags before processing and sampling29. Bats
were aged by observation of the epiphyseal–diaphyseal fusion63; sex and repro-
ductive status were also recorded. Saliva swab samples were collected by allowing
bats to chew on sterile cotton‐tipped wooden swabs (Fisherbrand) for 10 s. Whole
blood samples were also collected on swabs after puncturing the propatagial vein
with a sterile 23-gauge needle. All swabs were stored in either 1 ml RNALater
(Ambion), virus transport medium (VTM, phosphate-buffered saline supple-
mented with 10% foetal calf serum, and double-strength antibiotic/antimycotic
[200 U/ml penicillin, 200 g/ml streptomycin, and 0.5 g/ml fungizone amphotericin
B]) or phosphate-buffered saline (PBS), and then stored at −80 °C until further
analyses. All capture and sampling of bats were approved by the Research Ethics
Committee of the University of Glasgow School of Medical, Veterinary and Life
Sciences (Ref081/15) and by the University of Georgia Animal Care and Use
Committee (A2014 04-016-Y3-A5). Field collections were authorised by the Per-
uvian government (RD-009-2015-SERFOR-DGGSPFFS, RD-264-2015-SERFOR-
DGGSPFFS, RD-142-2015-SERFOR-DGGSPFFS, RD-054-2016-SERFOR-
DGGSPFFS). Livestock sample data were published previously (see data
availability).
Nucleic acid extraction. Nucleic acid extractions from swabs were performed on a
Kingfisher Flex 96 automated extraction instrument (ThermoFisher Scientific) with
the BioSprint One‐For‐All Vet Kit (Qiagen) using a modified version of the
manufacturer’s protocol for purifying viral nucleic acids from swabs29.
Amplification and Sanger sequencing of betaherpesviruses. Nucleic acid
extractions were analysed using a semi-nested PCR with primers that amplify a region
of the highly conserved terminase gene UL89: BHV-8F: 5′-TTC ATC TCG TCC ACC
AAC AC-3′ (round 1 and 2 forward primer), BHV-7R: 5′-TGT AGC GGA ACA
CGT CGA AC-3′ (round 1 reverse primer) and BHV-8R: 5′-CGA TGG TCT CGT
CCA TGA AG-3′ (round 2 reverse primer). Primers were adapted to be BHV-specific
from those used in Pozo et al.30. The PCR protocol was as follows: 94 °C for 2 min, 40
cycles of 94 °C for 30 s, 40 °C(round 1)/35 °C(round 2) for 3 min, 72 °C for 30 s, and a
final 72 °C for 5 min. HCMV was used as a positive control. The amplification of
BHV DNA was confirmed by gel electrophoresis (2% agarose in Tris-acetate-EDTA
buffer) examined for the presence of both round 1 (~315 bp) and round 2 (~219 bp)
bands of the expected size. A selection of positive round 1 and round 2 samples (all
non-D. rotundus samples and ~10% of D. rotundus saliva samples, numbers available
in Supplementary Table 2) were then purified using the QIAquick PCR purification
kit (Qiagen), and Sanger sequenced in both directions by Eurofins Genomics. For-
ward and reverse sequences, trimmed to remove primers and low confidence bases,
were assembled to create a 304 bp consensus sequence for each sample using CLC
Genomics Workbench v7.5 (https://digitalinsights.qiagen.com).
Molecular confirmation of bat species identities. Bat host species was confirmed
by sequencing a 450 bp cytochrome B sequence using the primers and PCR pro-
tocol from Martins et al.64. Briefly, Bat 05 A 5′-CGACTAATGACATGAAAAAT
CACCGTTG-3′; Bat 04 A 5′-GTAGCTCCTCAGAATGATATTTGTCCTC-3′ pri-
mers; 5 min at 94 °C, 35 cycles of 30 s at 94 °C, 45 °C for 45 s, 72 °C for 70 s and a
final step of 72 °C for 10 min. The samples tested were the A. lituratus, Di. ecaudata
and S. lilium saliva samples.
Amplification and sequencing of vampire bat rabies virus. 123 of the 128 D.
rotundus saliva samples that were tested for DrBHV were also tested by nested RT-
PCR for the presence of rabies virus. The five samples that were not tested had
insufficient nucleic acid extract for testing. The RT-PCR was carried as described
by Kuzmin et al.65 using primers found in Supplementary Table 6: RT step of 90
min at 42 °C, 40 PCR cycles of 30 s at 94 °C, 30 s at 37 °C, 90 s at 72 °C and a final
10 min at 72 °C.
Detection of rabies virus neutralising antibodies. To detect and quantify rabies
virus neutralising antibodies (RVNA), we used a pseudotype micro-neutralisation
rapid fluorescent focus inhibition test38. This test uses a combination of micro-
scopic imaging of cellular infectivity and generalised linear mixed modelling
(GLMM) to produce predicted RVNA titres in units of International Units/ml.
Samples were classified as seropositive or seronegative using a threshold of 0.166
IU/ml, which was previously shown to balance sensitivity and specificity most
appropriately38. GLMMs were fit using the lme4 package in R66. This yielded a
similar global seroprevalence to that observed in a previous study of Peruvian
vampire bats using the gold standard Rapid Fluorescence Focus Inhibition Test
(RFFIT)8.
Statistical analysis. Prevalence by species was assessed by using a point estimate
of the proportion of bats infected, with binomial confidence intervals (R (R studio
v1.1.456), binom package, method = bayes). A binomial generalised linear mixed
model (GLMM) followed by post-hoc pairwise comparisons of estimated pre-
valence by species was used to test the significance of differences in prevalence.
Within vampire bats (N= 128), the statistical significance of factors that may
influence DrBHV infection was tested, including age (adult, sub-adult or juvenile),
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sex (male or female), eco-region (Amazon, Andes or Coastal), year, season and
roost structure (single versus mixed-species roost). Statistical modelling used a
binomial GLMM employing the lme4 package of R66, with the site from which the
bat was captured treated as a random effect.
Phylogenetic inference. A dataset was constructed for phylogenetic analysis,
containing our own sequenced, and previously sequenced bat BHV sequences, and
containing BHV sequences from other mammalian species, including apes, mon-
keys, tree shrews and rodents. These sequences were acquired by conducting a
BLASTn search in GenBank (http://blast.ncbi.nlm.nih.gov/) using the DrBHV
sequenced samples and selecting a representative viral sequence from a range of
host species. The dataset included the relevant BHV human herpesvirus 6 A (genus
Roseolovirus, https://www.ncbi.nlm.nih.gov/nuccore/KY290185) sequence for use
as an outgroup, and can be found in full in Supplementary Table 7.
Consensus sequences from Sanger sequencing and those from GenBank were
aligned using MUSCLE (EMBL-EBI). The most likely evolutionary model (GTR+
gamma+invariant) was identified using jModelTest2 using the BIC criterion67.
Phylogenetic reconstruction was carried out using BEAST v1.10.4 and associated
software68. Markov chain Monte Carlo sampling of trees and parameters was run
for 10 million generations, sampling every 1000 generations. Posterior traces were
checked in Tracer v1.7.1 to evaluate convergence and select burn-in periods (10%
was selected). Consensus trees were constructed using TreeAnnotator and
visualised in FigTree v1.4.4 and R package ggtree69. Nucleotide sequences were also
converted to amino acid sequences and the phylogeny reconstructed using
Blosum62+G+ I in BEAST.
Co-phylogenetic analysis was used to identify the frequency of host switching
and co-divergence by employing the package PACo in R70. PACo returns a residual
sum of squares as an analysis of the Procrustean fit of the parasite (virus)
phylogeny to that of the host, as a measure of congruence between the two
phylogenies. Statistical significance was tested via a permutation test wherein the
host-parasite association matrix (each host and parasite matrix were first
normalised between 0 and 1 due to the differing scales of the two phylogenies) was
randomised and the residual sum of squares was calculated for each permutation.
The consensus BHV nucleotide- and amino acid-based trees, and 100 trees
randomly selected from the BEAST posterior distribution (excluding the burn-in),
were tested using this goodness-of-fit test for significance with 10,000 permutations
for the consensus tree and 1000 permutations each for the posterior trees, the
individual p-values from which were then averaged. This allowed assessment of co-
evolutionary relationships whilst accounting for uncertainty in the viral
evolutionary history. A jackknife procedure was used to estimate the squared
residual and its 95% confidence interval for each individual link. Host trees were
extracted from the mammalian super-tree71 in R using ape72. Ape was also used to
construct co-phylogenetic linkage plots of the consensus trees.
Whole genome sequencing and bioinformatics analysis. Two of the D. rotundus
samples that tested positive for BHV were selected for whole genome sequencing.
One sample (10148) was selected due to its strong PCR positive band on gel
electrophoresis. The second sample (10144) had a weaker band from PCR.
Together, these samples should be representative of different levels of infection by
DrBHV. DNA was extracted from each saliva swab sample both with and without
DNase treatment in order to remove host DNA, which can reduce the number of
host and bacterial reads and enrich viral reads in the final pool29. Sequencing
libraries were prepared using the DNA Library Preparation Kit for Illumina (KAPA
Biosystems) with index primers from New England Biolabs (NEB), and sequenced
on the Illumina NextSeq platform to produce approximately 40 million paired-end
reads of 150 bp (Supplementary Table 5).
Reads with significant BLAST similarity to the vampire bat genome, as well as
low-quality reads, were removed, and remaining reads were trimmed to remove
adaptors using trim_galore and diamond v0.9.25 as part of the allmond
bioinformatics pipeline for viral discovery (https://github.com/rjorton/Allmond).
Reads were then assembled into contigs using SPAdes v3.10.1 (de novo assembly),
Bowtie2 v2.3.5.1 and BWA v0.7.17 and samtools v1.9 (reference assembly). Contigs
were reference aligned to other BHV genomes retrieved from GenBank (HHV5,
NC_006273 (https://www.ncbi.nlm.nih.gov/nuccore/NC_006273); panine BHV 2,
AF480884(https://www.ncbi.nlm.nih.gov/nuccore/AF480884); murid BHV 1
NC_004065 (https://www.ncbi.nlm.nih.gov/nuccore/NC_004065); bat BHV B7D8,
JQ805139 (https://www.ncbi.nlm.nih.gov/nuccore/JQ805139)). A manual search
for sequence overlaps between contigs was then used to produce a nearly
continuous DrBHV genome sequence. Cleaned and filtered reads were
subsequently realigned to this sequence using Bowtie2 to increase coverage across
the genome. BLASTx was used to annotate the consensus genome sequence with
homologous genes from other BHVs. Open reading frames and corresponding
proteins were predicted using GeneMarkS73. The resulting proteins were compared
to those found in other BHVs (BLASTp), and those with a match were used to
annotate the genome using CLC Genomics Workbench v7.5.1 (https://
digitalinsights.qiagen.com). The raw reads were then re-aligned to the final
consensus DrBHV genome sequence in order to search for single nucleotide
polymorphisms (SNPs) that might indicate super-infection, using samtools
mpileup SNP calling (Supplementary Data 2). Only nucleotides with a coverage of
>10 reads were considered. In Fig. 5, phyloscanner was used to search for the
different sequences present in the 10148_KF29 and 10144_KF29 aligned reads, in
50 bp windows. This window size was selected to maximise the number of reads
that could be included, as a read must span the full window. Extracted reads were
visualised using R package ggtree.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Results of the betaherpesvirus PCR, rabies virus RT-PCR and rabies virus neutralising
antibody test, for Peruvian bats, generated and/or analysed during the current study are
available in the figshare repository https://doi.org/10.6084/m9.figshare.13090214. UL89
partial sequences used for phylogenies have been uploaded to GenBank, with the
following accession numbers: MT432305-16 and MT912480-93 (https://www.ncbi.nlm.
nih.gov/nuccore/MT432305, https://www.ncbi.nlm.nih.gov/nuccore/MT432306, https://
www.ncbi.nlm.nih.gov/nuccore/MT432307, https://www.ncbi.nlm.nih.gov/nuccore/
MT432308, https://www.ncbi.nlm.nih.gov/nuccore/MT432309, https://www.ncbi.nlm.
nih.gov/nuccore/MT4323010, https://www.ncbi.nlm.nih.gov/nuccore/MT4323011,
https://www.ncbi.nlm.nih.gov/nuccore/MT4323012, https://www.ncbi.nlm.nih.gov/
nuccore/MT4323013, https://www.ncbi.nlm.nih.gov/nuccore/MT4323014, https://www.
ncbi.nlm.nih.gov/nuccore/MT4323015, https://www.ncbi.nlm.nih.gov/nuccore/
MT4323016, https://www.ncbi.nlm.nih.gov/nuccore/MT912480, https://www.ncbi.nlm.
nih.gov/nuccore/MT912481, https://www.ncbi.nlm.nih.gov/nuccore/MT912482, https://
www.ncbi.nlm.nih.gov/nuccore/MT912483, https://www.ncbi.nlm.nih.gov/nuccore/
MT912484, https://www.ncbi.nlm.nih.gov/nuccore/MT912485, https://www.ncbi.nlm.
nih.gov/nuccore/MT912486, https://www.ncbi.nlm.nih.gov/nuccore/MT912487, https://
www.ncbi.nlm.nih.gov/nuccore/MT912488, https://www.ncbi.nlm.nih.gov/nuccore/
MT912489, https://www.ncbi.nlm.nih.gov/nuccore/MT912490, https://www.ncbi.nlm.
nih.gov/nuccore/MT912491, https://www.ncbi.nlm.nih.gov/nuccore/MT912492, https://
www.ncbi.nlm.nih.gov/nuccore/MT912493). The VBRV sequence from bat 6024 has the
accession number MT891038. The chimeric consensus sequence and aligned sequence
reads have been submitted to the SRA with bioproject ID: PRJNA631425, and run IDs,
SRR11789719-20 (https://trace.ncbi.nlm.nih.gov/Traces/sra/?run=SRR11789719, https://
trace.ncbi.nlm.nih.gov/Traces/sra/?run=SRR11789720). Source data are provided with
this paper.
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